Updates and Statements

02.08.2021

Pfizer and BioNTech Publish Data from In Vitro Studies in Nature Medicine Demonstrating COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with Key Mutations Present in U.K. and South African Variants

02.01.2021

Pfizer and BioNTech Publish Preclinical Data from Investigational COVID-19 Vaccine Program in Nature

01.29.2021

Pfizer and BioNTech Publish Data on COVID-19 Vaccine-Induced Antibodies’ Ability to Neutralize SARS-CoV-2 U.K. Strain Pseudovirus in Cell Culture in Science

01.26.2021

Statement on ATMI Ranking

01.20.2021

Pfizer and BioNTech Publish Results of Study Showing COVID-19 Vaccine Elicits Antibodies that Neutralize Pseudovirus Bearing the SARS-CoV-2 U.K. Strain Spike Protein in Cell Culture

01.15.2021

Statement on European Upscaling as well as Impact on Deliveries

01.15.2021

Statement by Pfizer Chairman and CEO Albert Bourla

01.08.2021

An In Vitro Study Shows Pfizer-BioNTech COVID-19 Vaccine Elicits Antibodies that Neutralize SARS-CoV-2 with a Mutation Associated with Rapid Transmission

12.17.2020

Pfizer COVID-19 Vaccine Production and Distribution Working Well

12.17.2020

Pfizer COVID-19 Vaccine Production and Distribution Working Well

12.15.2020

Pfizer Doses First Participants as Part of Global Achondroplasia Phase 2 Development Program

12.15.2020

Pfizer Doses First Participants as Part of Global Achondroplasia Phase 2 Development Program